Tag Archives: Keytruda

ESMO: Merck’s Keytruda doubles 5-year survival rate for lung cancer patients

Immuno-oncology competition has mounted this year in previously untreated, metastatic non-small cell lung cancer. But Merck’s Keytruda, the first PD-1/PD-L1 on the market in the setting, has new long-term survival results that the drugmaker hopes will help bolster its position. Keytruda doubled the five-year survival rate for patients whose tumors expressed levels of biomarker PD-L1… Read More »

FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

Print this page KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.– September 17, 2019 — (BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) approved the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima, the orally available kinase inhibitor discovered by… Read More »